Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders |
Mechanism ALK degraders(Anaplastic lymphoma kinase degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H53ClN10O10S |
InChIKeyWXNUIPVZMJMPNM-UHFFFAOYSA-N |
CAS Registry2229037-04-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | United States | 16 Apr 2018 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 16 Apr 2018 |





